Pay in 4 interest-free payments of $6.37 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
Although some semaglutide products are prescribed for people with type 2 diabetes, semaglutide belongs to the GLP-1 receptor agonist class and works differently from insulin injections
Semaglutide promotes bone formation through the activation of the Wnt/LRP5/-catenin signaling pathway (Figure 8)
Weeks 1-4: Initiation Phase Starting dose is low to minimize GI side effects Most patients notice reduced appetite within the first 1-2 weeks Mild nausea is common and typically improves within days Weight loss: 2-5 pounds (mostly water and initial caloric reduction) Key focus: Establish protein intake targets and begin resistance training if not already active Baseline DEXA scan and comprehensive bloodwork completed Months 2-3: Dose Escalation Dose increases every 4 weeks toward therapeutic range Appetite suppression becomes more consistent GI side effects may temporarily recur with each dose increase Weight loss: 1-2 pounds per week typical Patients often report improved energy, better sleep, reduced cravings Follow-up bloodwork to check metabolic markers Months 4-6: Therapeutic Phase Most patients have reached their maintenance dose Steady, consistent weight loss of 1-2 pounds per week Visible changes in body composition and clothing fit Metabolic markers (fasting glucose, triglycerides, HbA1c) typically improving Follow-up DEXA scan to verify fat loss vs
It is administered once a week by subcutaneous injection under the skin in the abdomen, thigh or upper arm
For others, this gentle pace is simply easier to manage, with fewer side effects and less strain
Medication class: Wegovy is a GLP-1 receptor agonist
US$ 22.56
US$ 21.14
US$ 21.86
US$ 20.15
